Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Queisser

Showing results (301-310 of 327) with videos related to

Pageof 33
Sort By:
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|March 19, 2014
Seasonality of congenital anomalies in EuropeJohannes Michiel Luteijn, Helen Dolk, Marie-Claude Addor, et al.
Angewandte Chemie (International Ed. in English)|August 20, 2021
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACsRobert P Law, Joao Nunes, Chun-Wa Chung, et al.
Nature|January 21, 2026
Identification of an allosteric site on the E3 ligase adapter cereblonVanessa N Dippon, Zeba Rizvi, Anthony E Choudhry, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in CellsPatrick J Brennan, Rebecca E Saunders, Mary Spanou, et al.
Genes & Development|May 21, 2024
Corrigendum: miR-182 integrates apoptosis, growth, and differentiation programs in glioblastomaFotini M Kouri, Lisa A Hurley, Weston L Daniel, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Genes & Development|April 4, 2015
miR-182 integrates apoptosis, growth, and differentiation programs in glioblastomaFotini M Kouri, Lisa A Hurley, Weston L Daniel, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|April 12, 2014
Epidemiology of multiple congenital anomalies in Europe: a EUROCAT population-based registry studyElisa Calzolari, Ingeborg Barisic, Maria Loane, et al.
Pageof 33

Showing results (301-310 of 327) with videos related to

Sort By:
Pageof 33
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|March 19, 2014
Seasonality of congenital anomalies in EuropeJohannes Michiel Luteijn, Helen Dolk, Marie-Claude Addor, et al.
Angewandte Chemie (International Ed. in English)|August 20, 2021
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACsRobert P Law, Joao Nunes, Chun-Wa Chung, et al.
Nature|January 21, 2026
Identification of an allosteric site on the E3 ligase adapter cereblonVanessa N Dippon, Zeba Rizvi, Anthony E Choudhry, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in CellsPatrick J Brennan, Rebecca E Saunders, Mary Spanou, et al.
Genes & Development|May 21, 2024
Corrigendum: miR-182 integrates apoptosis, growth, and differentiation programs in glioblastomaFotini M Kouri, Lisa A Hurley, Weston L Daniel, et al.
ACS Chemical Biology|July 6, 2017
Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer TargetManuel Ellermann, Ashley Eheim, Fredrik Rahm, et al.
Genes & Development|April 4, 2015
miR-182 integrates apoptosis, growth, and differentiation programs in glioblastomaFotini M Kouri, Lisa A Hurley, Weston L Daniel, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|April 12, 2014
Epidemiology of multiple congenital anomalies in Europe: a EUROCAT population-based registry studyElisa Calzolari, Ingeborg Barisic, Maria Loane, et al.
Pageof 33